NCT06594146View on ClinicalTrials.gov

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Primary Immune Thrombocytopenia
Interventions
BIOLOGICAL

CM313 injection

CM313

OTHER

placebo

placebo

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06594146 - Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter